Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine 0.05% Eye Drops for Sjögren's Syndrome-Related Dry Eye
ChiCTR2500099615Phase 4Completed
- Sponsor
- Peking University First Hospital
- Start
- Mar 2025
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cyclosporine in Sjögren's syndrome, dry eye syndrome (DED) and meibomian gland dysfunction (MGD), sponsored by Peking University First Hospital. Primary endpoints: Tear film break-up time (BUT) and Corneal fluorescein staining score. Started Mar 2025; status: completed.
02
Drugs
cyclosporine
03
Conditions
Sjögren's syndromedry eye syndrome (DED)meibomian gland dysfunction (MGD)
Beyond the preview
Go deeper on ChiCTR2500099615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500099615.